Form 4: BSX Executive Exercises Options, Sells Shares

Boston Scientific EVP Joseph Fitzgerald exercised 50,000 stock options and sold the resulting shares for a significant profit under a pre-established trading plan.

Summary

• Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp (BSX), reported changes in his beneficial ownership of company securities.
• On August 1, 2025, Fitzgerald acquired 50,000 shares of Common Stock by exercising stock options at a price of $26.15 per share.
• Concurrently, on August 1, 2025, he sold 50,000 shares of Common Stock at a weighted average price of $104.6334 per share.
• The sale price ranged from $104.16 to $105.10 per share.
• These transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
• Following these transactions, Fitzgerald directly owns 178,342 shares of Common Stock and indirectly owns 5,234 shares through a child, for which he disclaims beneficial ownership.
• He also beneficially owns 150,000 stock options after the exercise.

Sentiment

Score: 6

Explanation: The transaction is largely neutral for the company's outlook as it represents a pre-planned monetization of vested executive compensation. While it is an insider sale, the Rule 10b5-1 plan mitigates concerns about its signaling effect.

Positives

• The executive realized a substantial profit from the exercise of stock options and subsequent sale, with shares acquired at $26.15 and sold at an average of $104.6334.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned monetization of vested compensation rather than a reaction to immediate, non-public information.

Negatives

• An executive selling a significant number of shares (50,000) could be perceived as a slight negative signal, although mitigated by the pre-planned nature of the transaction.

Risks

• No specific risks are detailed in this Form 4 beyond the general market perception of insider selling, which can sometimes be interpreted negatively by investors.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

This filing details a routine insider transaction related to executive compensation and does not provide broader insights into industry trends or competitive dynamics within the medical technology sector.

Related Party Transactions

• The reporting person disclaims beneficial ownership of 5,234 shares held by his child, which are reported as indirect beneficial ownership.

Stakeholder Impact

• Shareholders may observe an executive selling a significant number of shares, but the pre-planned nature of the transaction under a Rule 10b5-1 plan suggests it is a routine compensation event rather than a signal of negative company performance.

Key Dates

Recommendation

The Form 4 details a pre-planned exercise and sale of vested stock options by an executive. While it represents an insider sale, the transaction was executed under a Rule 10b5-1 plan, suggesting it is a routine monetization of compensation rather than a signal of negative company performance or outlook. Therefore, it does not provide a strong basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Boston Scientific, BSX, Insider Trading, Form 4, Stock Options, Executive Compensation, Joseph Fitzgerald, Rule 10b5-1